Effects of a 5-HT4 receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2006, Pages 155-162

  Tutuian, R ^a   Mainie, I ^a   Allan, R ^b   Hargreaves, K ^b   Agrawal, A ^a   Freeman, J ^a   Gale, J ^b   Castell, D O ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD;

ADULT; AMPLITUDE MODULATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS FUNCTION; ESOPHAGUS MOTILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; MANOMETRY; MEAL; MEDICAL RECORD; PH; PRIORITY JOURNAL; VOLUNTEER;

ADULT; DOUBLE-BLIND METHOD; ELECTRIC IMPEDANCE; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; INDOLES; MALE; MANOMETRY; MIDDLE AGED; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 33745174812     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02968.x     Document Type: Article

References (33)

1. Locke GR Talley NJ Fett SL Zinsmeister AR Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997 112 : 1448 56.
2. DeVault KR. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol Clin North Am 1999 28 : 831 46.
3. Castell DO Kahrilas PJ Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 97 : 575 83.
4. Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991 3 : 151 62.
5. Tutuian R Vela MF Shay SS Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol 2003 37 : 206 15.
6. Tutuian R Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities. Study in 350 patients. Am J Gastroenterol 2004 99 : 1011 9.
7. Sifrim D Holloway R Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001 120 : 1588 98.
8. Prather CM Camilleri M Zinsmeister AR McKinzie S Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.
9. Kahrilas PJ Quigley EM Castell DO Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 1503 9.
10. Degen L Matzinger D Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001 15 : 1745 51.
11. Vela MF Tutuian R Katz PO Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003 17 : 243 51.
12. Crist J Gidda JS Goyal RK. Intramural mechanism of esophageal peristalsis: roles of cholinergic and noncholinergic nerves. Proc Natl Acad Sci U S A 1984 81 : 3595 9.
13. Murray JA Ledlow A Launspach J Evans D Loveday M Conklin JL. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 1995 109 : 1241 8.
14. Zhang X Tack J Janssens J Sifrim DA. Effect of sildenafil, a phosphodiesterase-5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function in cats. Neurogastroenterol Motil 2001 13 : 325 31.
15. Rhee PL Hyun JG Lee JH, et al. The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults. Am J Gastroenterol 2001 96 : 3251 7.
16. Hollis JB Castell DO. Effects of cholinergic stimulation on human esophageal peristalsis. J Appl Physiol 1976 40 : 40 3.
17. Humphries TJ Castell DO. Effect of oral bethanechol on parameters of esophageal peristalsis. Dig Dis Sci 1981 26 : 129 32.
18. Schuurkes JA Van Nueten JM Van Daele PG Reyntjens AJ Janssen PA. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther 1985 234 : 775 83.
19. Ruth M Hamelin B Rohss K Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 12 : 35 40.
20. Castell DO Sigmund C Jr. Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998 93 : 547 52.
21. Song CW UM SH Kim CD Ryu HS Hyun JH Choe JG. Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit. Scand J Gastroenterol 1997 32 : 541 6.
22. Bran S Murray WA Hirsch IB Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995 155 : 765 8.
23. Wysowski DK Corken A Gallo-Torres H Talarico L Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001 96 : 1698 703.
24. Ruth M Finizia C Cange L Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 15 : 1115 21.
25. Katschinski M Wank U Ducree M Schirra J Arnold R. Cisapride stimulates human esophageal motility. Digestion 1995 56 : 153 8.
26. Van Herwaarden MA Samsom M Van Nispen CH Verlinden M Smout AJ. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Aliment Pharmacol Ther 2000 14 : 453 62.
27. Fox M Fried M Menne D Stutz B Schwizer W. The effect of tegaserod on esophageal function: a randomized control trial in healthy volunteers. Gastroenterology 2005 128 ( Suppl. 2 A11 (abstract).
28. Sifrim D Castell D Dent J Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004 53 : 1024 31.
29. Sifrim D Holloway RH Tack J, et al. Effect of sumatriptan, a 5HT1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999 94 : 3158 64.
30. Coulie B Tack J Maes B Geypens B De Roo M Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 1997 272 : G902 8.
31. Houghton LA Fowler P Keene ON Read NW. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992 6 : 685 91.
32. Muller-Lissner SA Fumagalli I Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
33. Tack J Vos R Janssens J Salter J Jauffret S Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003 18 : 1031 7.